The Institute for Clinical and Economic Review (ICER) on Tuesday released a condition update report assessing the comparative clinical effectiveness and value of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis.
ICER previously reviewed treatments for plaque psoriasis in 2016.
In addition to incorporating new clinical data and updated costs for previously reviewed therapies, this condition update includes analyses of the recently approved medications guselkumab (Tremfya, Johnson & Johnson), tildrakizumab (Ilumya, Sun Pharma/Merck), and certolizumab pegol (Cimzia, UCB), as well as risankizumab (AbbVie), which was recently filed for review by the FDA.
“Our 2016 review found that all targeted therapies for plaque psoriasis are more effective than non-targeted agents, and that many are priced in alignment with the added benefit they provide patients. As a result, we urged insurers to consider limiting or altogether abandoning step therapy requirements for these agents,” noted Dan Ollendorf, PhD, Chief Scientific Officer at ICER. “In this update, which also looks at several additional new therapies, we find again that the evidence demonstrates relatively minor differences in overall effectiveness across all targeted agents. However, following two years of price increases since our original report, all older therapies have become significantly less cost-effective. Unfortunately, the newest approved therapies have been launched at prices that have tracked this upward trend and are therefore similarly overpriced in relation to their clinical value to patients.”
